Gottlieb: Brand Industry 'Gaming' Tactics Have Shifted
Former FDA Commissioner Sees Shift From Regulatory To Commercial Space
US FDA's focus on areas such as REMS abuse may have prompted certain brand sponsors to shift their focus to the commercial space to keep generic competition off the market, former commissioner Scott Gottlieb tells the Association for Accessible Medicines.
You may also be interested in...
Teva Launches First-Ever CREATES Act Suit
Amicus should to be forced to sell samples of Galafold (migalastat) for bioequivalence and other testing, Teva argues in what appears to be the initial case brought under the 2019 law intended to smooth the development of ANDAs.
REMS Abuse Website: Has It Changed The Behavior Of Innovators?
Updated numbers from the US FDA's REMS abuse website show that Celgene has received two additional safety determination letters, raising question's about whether the public list has changed the practices of brand companies hindering generic company access to samples.
REMS Abuse Website: All Sizzle, No Steak?
AAM President Davis contends he hasn't seen any evidence showing that reference listed drug access inquiries webpage has changed innovator behavior.